Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
Sponsor: Rambam Health Care Campus
Summary
This is a randomized placebo-controlled trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity
Official title: Pre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Crohn's Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2023-04-24
Completion Date
2026-12-31
Last Updated
2025-04-04
Healthy Volunteers
No
Interventions
Azithromycin Pill
Tablet - 500 mg azithromycin (as dihydrate)
Placebo
Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
Locations (9)
Soroka University Medical Center
Beersheba, Israel
Bnei Zion
Haifa, Israel
Carmel Medical Center
Haifa, Israel
Rambam Health Care Campus
Haifa, Israel
Wolfson Medical Center
Holon, Israel
Hadassah Medical Center
Jerusalem, Israel
Shaare Zedek
Jerusalem, Israel
Zvulun
Kiryat Bialik, Israel
Rabin Medical Center
Petah Tikva, Israel